Study of Acalabrutinib versus Chlorambucil plus Rituximab in Adult Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Trial Identifier: D822BC00001
Sponsor: AstraZeneca
NCTID:: NCT04075292
Start Date: January 2020
Primary Completion Date: June 2024
Study Completion Date: June 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN beijing, CN, 100191
CN Changchun, CN, 130021
CN Changsha, CN, 410013
CN changzhou, CN, 272100
CN Fuzhou, CN, 350001
CN Guangzhou, CN, 510515
CN Guangzhou, CN, 510100
CN Guiyang, CN, 550004
CN Hangzhou, CN, 310003
CN Hefei, CN, 230031
CN Hefei, CN, 230001
CN Lanzhou, CN, 730030
CN Nanchang, CN, 330006
CN Nanjing, CN, 210029
CN Qingdao, CN, 110016
CN Shanghai, CN, 200025
CN Shanghai, CN, 200040
CN Shanghai, CN, 200050
CN Shenyang, CN, 110001
CN Shijiazhuang, CN, 050020
CN suzhou, CN, 215006
CN taiyuan, CN, 030001
CN tianjin, CN, 300020
CN Xuzhou, CN, 221000
CN Zhengzhou, CN, 450008
CN Zhengzhou, CN, 450052
PH Baguio City, PH, 2600
PH Cebu, PH, 6000
PH Davao City, PH, 8000
PH Legazpi City, PH, 4500
PH Makati, PH, 1229
PH Manila, PH, 1000
PH Quezon City, PH, 1112
TH Bangkok, TH, 10330
TH Bangkok, TH, 10400
TH Bangkok, TH, 10700
TH Chiang Mai, TH, 50200
TH Hat Yai, TH, 90110
TH Khon Kaen, TH, 40002
TW Chiayi, TW, 613
TW Hualien City, TW, 97002
TW Kaohsiung, TW, 833
TW Taichung, TW, 40705
TW Taichung, TW, 404
TW Tainan, TW, 704
TW Taipei, TW, 11217
TW Taipei, TW, 10002
TW Taoyuan City, TW, 333
VN Hanoi, VN, 100000
VN Ho Chi Minh, VN, 700000
VN Ho Chi Minh city, VN